Athira Pharma to undergo 10-for-1 reverse stock split on Sept. 17.

Athira Pharma will effect a 10-for-1 reverse stock split of its issued and authorized common stock. The reverse stock split will become effective on September 17, 2025, and the company's common stock is expected to begin trading on a split-adjusted basis on Nasdaq on September 18, 2025. The move aims to increase the liquidity and marketability of Athira's shares.

Athira Pharma, Inc. (NASDAQ: ATHA) has announced a 10-for-1 reverse stock split of its issued and authorized common stock. The reverse stock split, which was approved by shareholders at the company's Annual Meeting of Stockholders on May 29, 2025, will become effective on September 17, 2025, at 5:00 p.m. Eastern Time Athira Pharma Announces Reverse Stock Split^[1]. As a result, Athira's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the open of trading on September 18, 2025.

The reverse stock split is designed to increase the price per share of Athira's common stock, which is currently trading below the $1.00 minimum bid price requirement for continued listing on Nasdaq. This move aims to enhance the liquidity and marketability of the company's shares, potentially attracting a broader range of investors.

Under the reverse stock split, every ten (10) shares of Athira's issued and outstanding common stock will be combined into one issued and outstanding share of common stock. Consequently, the total number of authorized shares will be reduced from 900,000,000 to 90,000,000. The par value per share of Athira's common stock will remain unchanged at $0.0001. Proportional adjustments will be made to the exercise price and the number of shares of common stock issuable upon the exercise of the Company’s outstanding options, to the shares of common stock issuable upon the vesting of the Company’s outstanding restricted stock units, and to the number of shares authorized and reserved for issuance pursuant to Athira’s equity incentive plans. The total number of authorized shares of preferred stock will not be reduced and remains at 100,000,000 shares. Any fractional shares resulting from the reverse stock split will be paid out in cash.

Athira's transfer agent, Computershare Inc., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of Athira’s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in "street name" will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular processes, and will not be required to take any action in connection with the reverse stock split.

Athira Pharma is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. The company aims to alter the course of neurological diseases by advancing its pipeline of drug candidates that modulate the neurotrophic HGF system. For more information, visit www.athira.com.

Additional information about the reverse stock split is available in Athira’s definitive proxy statement filed with the Securities and Exchange Commission on April 14, 2025, a copy of which is available at www.sec.gov.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

Athira Pharma Announces Reverse Stock Split^[1]: https://www.marketscreener.com/news/athira-pharma-announces-reverse-stock-split-ce7d59d2d88cff23